London, UK, 09 February 2021; Antev Ltd (“Antev” or “the Company”), a late clinical-stage drug development company advancing the drug teverelix to treat prostate cancer and related indications, today announces the appointment of Amit Kohli as Chief Executive Officer (“CEO”).

Mr Kohli will be responsible for leading Antev’s corporate strategy and operational and clinical development and will oversee the Company’s advance along the clinical pathway towards commercialisation for its lead indication, teverelix, a novel gonadotrophin releasing hormone (“GnRH”) antagonist for the treatment of hormone sensitive advanced prostate cancer.

With over 25 years of senior executive and leadership roles across both public and private companies operating within the healthcare sector, Mr Kohli has strong cross functional experience that straddles clinical drug development, regulatory affairs, manufacturing, sales, marketing and finance.

“Amit comes to us from multiple senior executive positions in the life science industries. With his breadth of experience spanning key facets of our industry and at an exciting and important stage in Antev’s development, we are delighted to welcome him and very much look to benefitting substantially from his commercial vision and clinical development background”, said Oliver Bates, Co-Founder and Non-Exec Chairman of Antev Limited.

“I am delighted to join Antev at a key stage in the company’s development,” commented Mr Kohli. “Teverelix, a novel GnRH Antagonist, offers a potential life-saving treatment for hormone sensitive advanced prostate cancer patients. I am very excited by the Phase 2 clinical advance of teverelix , validating its well differentiated profile that will give Urologists and Uro-Oncologists an option to administer a longer acting, efficacious treatment, which has a milder side-effect profile, driving higher compliance. Furthermore, FDA/EMA guidelines allow a quick and cost-effective pathway towards regulatory approval with a single arm pivotal trial of teverelix. This represents an optimum route for Antev and its investors to see the rapid development of its technology towards commercialization. I and Antev’s talented team look forward to taking the company on to its next exciting stage.”

Before joining Antev, Mr Kohli was Chief Operating Officer at Pharnext SA (“Pharnext”), a Euronext listed advanced clinical-stage biopharmaceutical company, developing novel therapeutics for orphan neurodegenerative disorders. At Pharnext, Mr Kohli was responsible for leading corporate strategy and operations.

Prior to Pharnext, Mr Kohli held leadership roles at Eurofins, Becton Dickinson and at Sanofi, encompassing sales, marketing, supply chain and manufacturing.

Mr. Kohli earned an M.B.A. from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Engineering from the University of Pune in India.

Download as PDF